Genmab to receive $30 million milestone payment from Janssen

31 May 2016

Danish biotech firm Genmab (OMX: GEN) says it has achieved a $30 million milestone in its Darzalex (daratumumab) collaboration with Janssen Biotech, a subsidiary of US healthcare giant Johnson & Johnson (NYSE: JNJ).

The milestone payment was triggered by the first commercial sale of Darzalex in Europe. The European Commission (EC) recently granted a conditional marketing authorization for first-in-class CD38 immunotherapy Darzalex for use as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.

“We continue to be impressed by the rapid speed with which our collaboration partner, Janssen, has been able to develop and launch Darzalex in Europe,” said Jan van de Winkel, chief executive of Genmab.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK